Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
US9795574B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9795574-B2 |
| Application number | US-201515323063-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 30, 2015 |
| Priority date | Jun 30, 2014 |
| Publication date | Oct 24, 2017 |
| Grant date | Oct 24, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides a preparation method for agomelatine-resorcinol and agomelatine-hydroquinone co-crystals using the solvent-antisolvent method that enables a commercial mass production. The co-crystals prepared by the preparation method of the present invention displays high dissolution rate and high stability in acidic-to-neutral media.
Opening claim text (preview).
The invention claimed is: 1. A method for preparing agomelatine-resorcinol or agomelatine-hydroquinone co-crystals, the method comprising: (i) dissolving agomelatine and one aromatic polyhydric alcohol selected from hydroquinone and resorcinol in an organic solvent selected from the group consisting of C3-C7 ester, C2-C7 ether and a mixture thereof to prepare a solution; and (ii) adding a solvent selected from the group consisting of C5-C7 alkane, benzene and a mixture thereof as an antisolvent to the solution of the step (i) to prepare a mixture. 2. The method of claim 1 , wherein the agomelatine-resorcinol co-crystal has a powder X-ray diffraction pattern showing peaks (±0.2°) at Bragg angles (2 theta) of 7.25°, 7.95°, 8.35°, 14.45°, 16.70°, 17.35°, 17.95°, 19.05°, 19.95°, 21.30°, 21.75°, 22.50°, 23.75°, and 24.40°. 3. The method of claim 1 , wherein the agomelatine-resorcinol co-crystal has a single endothermic peak in the differential scanning calorimetry (DSC) curve at 88° C. 4. The method of claim 1 , wherein the agomelatine-hydroquinone co-crystal has a powder X-ray diffraction pattern showing peaks (±0.2°) at Bragg angles (2 theta) of 10.40°, 17.00°, 17.50°, 18.00°, 19.25°, 20.10°, 21.00°, 21.30°, 21.75°, 22.10°, 23.55°, 24.15°, and 26.20°. 5. The method of claim 1 , wherein the agomelatine-hydroquinone co-crystal has a single endothermic peak in the differential scanning calorimetry (DSC) curve at 97° C. 6. The method of claim 1 , wherein the solution comprises agomelatine and resorcinol or hydroquinone at a molar ratio of 1:1 to 1:2. 7. The method of claim 1 , wherein the organic solvent is at least one selected from the group consisting of methylacetate, ethylacetate, diethylether, methyl-tert-butylether, and a mixture thereof. 8. The method of claim 1 , wherein the antisolvent is at least one selected from the group consisting of pentane, hexane, heptane, benzene, and a mixture thereof. 9. The method of claim 1 , further comprising: stirring the mixture of the step (ii).
Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent · CPC title
having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton · CPC title
from compounds not provided for in groups C07C231/02 - C07C231/08 · CPC title
Crystalline forms, e.g. polymorphs · CPC title
having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.